ARTICLE | Financial News

CureVac raises $110M in private placement

November 4, 2015 2:15 AM UTC

CureVac AG (Tuebingen, Germany) raised $110 million in a private placement led by new investor Baillie Gifford. New investors Chartwave Ltd., Coppel Family, Elma Investments Ltd. and Sigma Group also participated, as did existing investors dievini Hopp BioTech holding GmbH & Co. KG and the Bill & Melinda Gates Foundation.

Chief Corporate Officer Franz-Werner Haas told BioCentury the company expects data in 2H16 from a Phase IIb study of its lead candidate, prostate cancer vaccine CV9104. The company has discussed out-licensing the modified mRNA vaccine targeting six antigens overexpressed in prostate cancer, but Haas said the financing gives CureVac the flexibility to pursue a Phase III program independently. ...